George Talbot, MD

Talbot Advisors LLC

Disclosure(s): AN2 Therapeutics, Inc.: Advisor/Consultant, Co-founder

Poster(s):

• 1727 - Phase 1b Dose-ranging Study Demonstrates Tolerability and Pharmacokinetics (PK) of Oral Epetraborole at the Predicted Therapeutic Dosage for Mycobacterium avium Complex (MAC) Lung Disease
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET